Mats Blom to Board as Chair of Audit Committee

Avacta names Mats Blom Audit Committee Chair, succeeding Paul Fry this month.

What the company is saying

Avacta Group plc has appointed Mats Blom to its Board of Directors and as Chair of the Audit Committee, effective September 14, 2026. The company frames this as a strengthening of governance and financial oversight, highlighting Blom’s experience as CFO at multiple listed and private biotech firms, including a nine-year tenure at Zealand Pharma A/S where he managed two stock exchange listings. Paul Fry, the outgoing Audit Committee Chair, will step down effective September 30, 2026, with the transition described as orderly. CEO Christina Coughlin emphasizes Blom’s financial expertise and international sector background as instrumental for advancing Avacta’s pre|CISION® oncology platform and achieving clinical and strategic milestones. The announcement uses confident, forward-looking language about pipeline progress and value creation but does not tie these to the appointment with specific outcomes. The company explicitly states that Blom holds no ordinary shares in Avacta.

What the data suggests

The announcement provides concrete governance changes: Mats Blom, age 61, joins the Board and becomes Audit Committee Chair as of September 14, 2026, while Paul Fry will depart September 30, 2026. Blom’s credentials include CFO roles at Zealand Pharma A/S (2010–2019), Active Biotech, Anoto Group, and several private biotech companies, as well as current board positions at Egetis Therapeutics AB, Hansa Biopharma AB, and Pephexia Therapeutics ApS. No financial performance data, operational metrics, or clinical trial results are disclosed. The only quantitative details relate to appointment dates, tenure, and Blom’s lack of shareholding. The company’s lead clinical asset, AVA6000, is referenced as having shown preliminary activity in certain cancer types, but no new data or milestones are presented. The narrative is factual and avoids exaggeration, with no evidence of overstated claims.

Analysis

This announcement is a routine Board and management update, disclosing the appointment of Mr. Mats Blom as a new Board member and Audit Committee Chair, with the orderly transition from Mr. Paul Fry. The language is positive but proportionate, focusing on Mr. Blom's credentials and experience. While there are a few forward-looking statements about supporting the company's mission and advancing its platform, these are generic and expected in such releases, not tied to any specific operational or financial milestone. No financial results, operational updates, or capital outlays are disclosed, and there is no attempt to inflate the significance of the appointment beyond its governance context. The data provided is factual, with specific dates and biographical details, and does not overstate realised progress or future benefits. There is no gap between narrative and evidence, as the announcement does not make investment claims.

Risk flags

• ●Key-person transition risk exists as Paul Fry departs after seven years, requiring Blom to rapidly assume oversight of the Audit Committee. This could create short-term continuity challenges if there are unresolved audit or governance issues.
• ●Blom holds no ordinary shares in Avacta, which may limit direct alignment with shareholder interests until or unless he acquires a stake. While not unusual, this can be a governance consideration for some investors.
• ●The announcement provides no detail on the current state of Avacta’s financial controls or audit processes, so it is unclear whether Blom is inheriting a stable or challenged governance environment. The absence of such context leaves a gap in assessing the true significance of the appointment.

Bottom line

This is a routine board succession announcement, with Mats Blom, a seasoned biotech CFO and board member, replacing Paul Fry as Audit Committee Chair. The transition is structured and imminent, but the release contains no new financial, clinical, or operational data to inform an investment view. Blom’s track record in public biotech governance is credible, but his lack of shareholding and the absence of detail on Avacta’s current audit environment limit immediate investor insight. The announcement signals a focus on governance continuity rather than a strategic shift. Investors should not expect near-term impact from this change alone; the most relevant future disclosures will be clinical or financial updates tied to Avacta’s pipeline progress.

Announcement summary

(AIM: AVCT) Avacta Group plc announced the appointment of Mr. Mats Blom as a member of its Board of Directors and Chair of the Audit Committee, effective September 14, 2026. Mr. Paul Fry has indicated his intention to step down from the Board effective 30 September 2026, allowing for an orderly transfer of responsibilities to Mr. Blom. Mr. Blom is an experienced biotechnology finance executive and Board member, having served as Chief Financial Officer at Zealand Pharma A/S from 2010-2019, where he oversaw its listing on Nasdaq and previous initial public offering on Nasdaq OMX Copenhagen. He was also CFO of Active Biotech and Anoto Group, and private companies NorthSea Therapeutics USA Inc, Modus Therapeutics, and Swedish Orphan International. Mr. Blom is currently Chairman of the Board of Egetis Therapeutics AB, Board member at Hansa Biopharma AB, and Board member at Pephexia Therapeutics ApS. He was previously a Board member at Altamira Therapeutics. Mr. Blom holds a BA in Business Administration and Economics from Lund University and an MBA from the IESE University of Navarra, Barcelona. Avacta's lead clinical program is faridoxorubicin (AVA6000), a Gen One FAP-enabled pre|CISION® version of doxorubicin that has demonstrated preliminary activity in tumor types sensitive to doxorubicin including salivary gland cancer and soft tissue sarcoma. Mr. Blom currently holds no ordinary shares in the Company.

Disagree with this article?